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Abstract 
The aim of this study was to develop a formulation, containing the propolis standardized 
extract (EPP-AF®), which can assist in the healing of skin lesions. To achieve this objective the 
antimicrobial activity and chemical composition of the propolis extract was determined. The 
final product was subjected to in vitro and in vivo pre-clinical evaluation. The broth macrodi-
lution method was used to determine the antimicrobial activity of the extracts and formula-
tions against the microorganisms most commonly found in burns, Pseudomonas aeruginosa, 
Klebsiella pneumoniae, Escherichia coli, Staphylococcus aureus and Staphylococcus epidermidis. 
Wistar rats with puncture wounded skin were used to evaluate the wound healing properties 
of propolis. The results of chemical and biological characterization demonstrated the 
batch-to-batch reproducibility of the standardized extract which is an unprecedented result. 
The antimicrobial and wound healing activity of the pharmaceutical studied showed the best 
results when samples contain 3.6% propolis, suggesting that this is the most promising 
composition. 
Key words: propolis, EPP-AF®, antimicrobial activity, wound healing, pharmaceutics, reproduci-
bility 
Introduction 
Thermal injury is a major cause of morbidity and 
impaired quality of life in many areas of the world. 
Each year in The United States of America, more than 
1.25 million people suffer burns. It has been estimated 
that 75% of deaths following burn injuries are related 
to infection [1]. 
The optimal dressing for the outpatient treat-
ment of partial-thickness thermal burns continues to 
challenge emergency physicians and surgeons. While 
the ideal dressing material should be of low cost, safe 
and relatively painless, it should also discourage in-
fection and promote fast wound healing to minimize 
morbidity and optimize functional and cosmetic out-
comes. Furthermore, to increase outpatient compli-
ance, the number of dressing changes should be 
minimized and be easily performed at home with the 
slightest amount of discomfort [2].  
Nalbandian et al. (1987) developed a poloxamer 
407 gel for dermatological and burn treatment, be-
cause of its water solubility, adherence and easy ap-
plication and removal from the burn sites [3]. 
Poloxamer 407 is an inert, atoxic substance that is able 
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to generate thermoreversible colloidal solutions in the 
presence of water, as a consequence of its aggregation 
into micelles, which occurs with increasing tempera-
ture, minimizing the free energy of the solution. At 
low temperatures, the polymer exists as a monomer in 
solution. Upon warming, a balance is established 
between monomers and micelles, and aggregates are 
formed [4].  
In addition to the need for more convenient 
wound dressing and pharmaceuticals, it is also im-
portant to discover therapeutic agents that are more 
effective against microbial infections frequently re-
lated with burns.  
Propolis is a resinous balsamic material, with a 
complex chemical composition, which is collected by 
bees from sprouts, exudates of trees and other parts of 
the plants. It is modified in the beehive by addition of 
salivary secretions and wax [5]. It is used by bees for 
protection, repair of holes and damage to the hive, 
and for the construction of aseptic places for the 
queen to lay her eggs [6]. More than 150 components, 
including polyphenols, terpenoids, steroids, sugars 
and amino acids, have been identified in raw propolis. 
Its chemical composition is influenced by botanical 
and geographical factors, as well as the collection 
season. In general, propolis consists of 50% resin and 
vegetable balsam, 30% wax, 10% essential and aro-
matic oils, 5% pollen, and 5% other substances in-
cluding organic debris [7]. 
Several studies have been published on the 
many different existing propolis extracts, both with 
regard to their biological activities [8-10] and safety 
[7]. However, it is impossible to compile all data for 
the generation of a pharmaceutical product. The 
origin, composition and extractive processes alter the 
extract obtained and subsequently biological behavior 
of the product. Therefore, the propolis standardized 
extract (EPP-AF®) used in this study offers some ad-
vantages over the others, since some of its biological 
activities [5; 11-14] and safety [11] have been studied 
previously in other models, which allowed greater 
security for the realization of this proposal. 
The EPP-AF® showed anti-inflammatory [11], 
anti-ulcer [12], antimicrobial [13], antioxidant [5] and 
antifungal activities [14]. Furthermore, its safety has 
been demonstrated [11] and the absence of cytotoxi-
city and mutagenic potential evaluated [15-16]. With 
the data available, all obtained from the same extract 
with the same composition of the propolis raw mate-
rial, and the same chemical extracting process, it is 
possible to get a drug. Aiming to achieve this goal, 
this study proposed to evaluate three batches of 
EPP-AF® assessing its chemical composition and bio-
logical properties in order to determine the repro-
ducibility of the product batch-to-batch. 
For wound dressing application, several poly-
meric materials have been investigated with success-
ful outcomes, but an ideal skin substitute with struc-
tural and functional properties similar to those of 
human skin requires further investigated [17].  
Considering this information, a pharmaceutical 
compound was developed, containing the propolis 
extract, designed to be used for treating wounds, as a 
product suited for this application is still required. In 
addition to the chemical characterization of the prop-
olis extracts and evaluation of its reproducibility, the 
final product was subjected to in vitro (antimicrobial 
activity) and in vivo (wound healing) pre-clinical 
evaluation.  
Materials and Methods 
Chemicals 
Three batches of green propolis standardized 
extracts (EPP-AF®): A (010/08), B (1440110) and C 
(1400410), were kindly provided by Apis Flora Co. 
(Ribeirão Preto, São Paulo, Brazil) (patent PI 
0405483-0, Revista de Propriedade Industrial No. 1778 
of 01/02/2005). Propolis glycolic extract (PGE) was 
obtained from EPP-AF® after evaporation of the eth-
anol portion and the addition of propyleneglycol to 
achieve 30% w/v of dry matter. For quantitative 
analysis caffeic, p-coumaric and trans-cinnamic acids 
(Sigma-Aldrich , São Paulo, Brazil); artepillin C (Wako 
Pure Chemical Industries Co., Osaka, Japan); gallic 
acid (Labsynth, Diadema, Brazil); isosakuranetin 
(ChromaDex, Irvine, Canada) and aromaden-
drin-4´-O-methyl ether (previously isolated and iden-
tified as described by Sousa et al. [18] and kindly do-
nated by the authors) were used. Methanol 
HPLC-grade was obtained from J.T. Baker and water 
was treated in a Milli-Q water purification system. All 
other chemicals were of reagent grade and were used 
without further purification. Mueller Hinton agar and 
Mueller Hinton broth (Difco, Detroid, MI, USA), were 
used for the microbial assays. 
Chemical Analysis of propolis extracts by 
HPLC  
The propolis extracts were analyzed by HPLC 
using a Shimadzu apparatus equipped with a 
CBM-20A controller, a LC-20AT quaternary pump, a 
SPD-M 20A diode-array detector, and Shimadzu LC 
solution software, version 1.21 SP1. A Shimadzu 
Shim-Pack CLC-ODS column (4.6 mm x 250 mm, par-
ticle diameter of 5 µm, pore diameter of 100 Å) was 
used. The mobile phase consisted of methanol (B), and 
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of a solution of water-formic acid (0.1% v/v), pH 2.7 
(A). The method consisted of a linear gradient of 
20-95% of B over a period of 77 minutes at a flow rate 
of 0.8 ml/min. Detection was set at 275 nm. 
Propolis extracts were diluted with 5 ml of 
methanol (HPLC grade) in 10 ml volumetric flasks, 
subjected to sonication for 10 minutes and filled to 
volume with Milli-Q water. The samples were filtered 
through a 0.45 µm filter before analysis. 
Preparation of thermoreversible formulations 
The raw material used for the formulations in-
cluded the polymer poloxamer 407, a co-surfactant 
ethoxylated castor oil (BASF, São Paulo, Brazil) so-
dium sorbate (Labsynth, Diadema, Brazil) and water. 
The gels (patent PI 0806114-9) were prepared on a 
weight basis using the cold method according to 
Schmolka [19]. Appropriate amounts of PGE and 
co-surfactant were mixed to yield 1.2, 2.4 and 3.6% 
(w/w) dry propolis extract (samples 1, 2 and 3, re-
spectively), in accord with previous publication by 
our group [15]. Two control samples were prepared: 
one consisting of the polymer dispersion in water 
(control 1) and the other of polymer and co-surfactant 
in water (control 2) at concentrations same to those 
used for the propolis gels.  
Antimicrobial activity 
Pseudomonas aeruginosa ATCC 27853, Klebsiella 
pneumoniae ATCC 10031, Escherichia coli ATCC 25922, 
Staphylococcus aureus ATCC 25923, Staphylococcus au-
reus ATCC 43300, and Staphylococcus epidermidis 
ATCC 14990 were acquired from the American Type 
Culture Collection (ATCC). 
The three batches of EPP-AF® (A, B and C) and 
the formulations (samples 1, 2 and 3) containing the 
PGE extracts respectively, and the controls (1 and 2) 
were evaluated.  
The antimicrobial activity of the EPP-AF® and 
formulations were determined by the broth macrodi-
lution method [20] with some adaptations for natural 
products. Sterile test tubes and Mueller Hinton broth 
were used for the tests. 
As a result of the turbidity that occurred in test 
broth when EPP-AF® was diluted, it was not possible 
to determine the minimum inhibitory concentration 
(MIC). Therefore, the antimicrobial activity of the 
EPP-AF® was assessed by means of the minimum 
bactericidal concentration (MBC), which was deter-
mined by subculturing 20 l aliquots from each tube 
in the broth dilution series onto Mueller Hinton agar 
plates. The plates were incubated at 35°C for 24 h. The 
MBC was defined as the lowest concentration of the 
sample required to kill the microorganism being 
tested. In the case of the gels, this turbidity does not 
occur and therefore the antimicrobial activity was 
determined by MIC [20]. 
In vivo models for wound healing activity 
Thirty male Wistar rats (Rattus norvegicus, 
Berkenout, 1769) with an initial body weight of 45 g, 
obtained from the Central Animal House, Faculty of 
Medicine of Ribeirão Preto, University of São Paulo, 
Brazil, were used. The protocol was approved by the 
Ethics Committee for Animal Care of the University 
of Franca (process 121/05). 
A lesion was created with a punch on the back of 
animals previously anesthetized by intraperitoneal 
administration of ketamine, midazolam and acepram 
[21]. After surgery the animals received no additional 
treatment (antibiotics or anti-inflammatory drugs), 
only food and water ad libitum. The cages were 
cleaned daily and kept in air conditioned environ-
ment. The concentrations of the propolis extract 
added to the formulations used in the present study 
were established based on ethnopharmacological in-
formation [22]. The animals were treated with gels in 
the presence and absence of propolis (EPP-AF®) (n = 
3). The animals were fed and weighed daily. 
The healing process was evaluated by two ex-
perimental protocols. At first, there was a single ap-
plication of the product under test, and the animals 
were sacrificed three days after the completion of the 
surgical incision (n = 3). In the second protocol, the 
products were applied twice a day (each 12 hours), 
and the animals were sacrificed three days after inci-
sion (n = 3). 
The animals were sacrificed with lethal doses of 
anesthetic and the tissue containing the lesions were 
fixed in 4% formaldehyde in Sorensen phosphate 
buffer 0.1 M, pH 7.3. The samples were placed in 
paraffin and sliced by a microtome in slices of 6 µm. 
The sections were stained with Masson trichrome 
staining and analyzed by optical microscopy [23]. 
The micro measurements of the affected area 
were performed using three sections per rat with 25 
µm of distance between each section totaling 93 µm 
per treatment. The morphometry of the lesion, in all 
groups and treatments, was evaluated using an image 
analyzer KS300 - Zeiss (Axion Vision) with a 40x 
magnification. The results are presented as mean tis-
sue filler by micrometers. 
Statistical analysis 
The statistical analysis was performed by the 
Pearson correlation coefficient (r) obtained by the 
correlation of the markers in three batches studied 
(n=4). The r2 value was expressed as percentage of 
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correlation. The Pearson´s coefficients obtained were 
subjected to analysis of variance (ANOVA) with 
Bonferroni multiple comparison post-test (level of sig-
nificance of 5%). The data of the antimicrobial activity 
were submitted to the nonparametric Kruskal-Wallis 
test (significance level of 1%). Statistical analysis of 
data was performed using the software Graph Pad 
Prism 4. 
Results 
Chemical characterization of EPP-AF® 
Correlation analyses indicated that there was a 
significant relationship between batch A and B 
(99.61%), B and C (99.72%), and between A and C 
(99.71%), demonstrating the chemical reproducibility 
of the three batches (p>0.05). The chemical character-
ization results demonstrate that the three batches 
studied were similar, since the presence and quanti-
fication of the six standards studied (caffeic, 
p-coumaric and trans-cinnamic acids, aromadendrin, 
isosakuranetin and artepillin C) were similar 
batch-to-batch (p>0.05).  
Table 1 and Figure 1 show the quantitative 
analysis of the three batches of EPP-AF® and their 
chromatograms, respectively. 
 It is important to point out that the chemical 
markers quantified represent three important groups 
of metabolites commonly found in propolis products: 
the flavonoids, the prenilated phenolic compounds 
and phenolic acids. The unidentified peaks in the 
chromatograms are undergoing further investigation. 
Nonetheless, the chemical markers used in this study 
are distributed along the chromatogram allowing 
more confidence for chemical profile analysis. 
 
 
 
Table 1 Chemical characterization of the standardized 
propolis extracts (EPP-AF®) used in this study (n=4) (mg/g). 
Compounds Standardized Propolis Extract 
Aa Bb Cc 
caffeic acid 0.299  0.024 0.336  0.027 0.288  0.009 
p- coumaric acid 1.561  0.090 1.524  0.108 1.486  0.052 
trans-cinnamic acid 0.091  0.055 0.167  0.001 0.153  0.009 
aromadendrin 1.020  0.168 0.993  0.075 1.125  0.022 
isosakuranetin 2.261  0.135 2.256  0.144 2.265  0.084 
artepilin C 7.553  1.497 8.533  0.522 6.962  0.261 
a Batch 010/08 of EPP-AF®.  
b Batch 1440110 of EPP-AF®.  
c Batch 1400410 of EPP-AF®. 
 
 
 
Figure 1: Chromatographic profile of (a) Propolis Standardized 
Extract (EPP-AF®) Batch 1440110 ; (b) Batch 1400410 and (c) 
Batch 010/08. Chromatographic profile includes the compounds: 
1. Caffeic acid (around 15 min.); 2. p-coumaric acid (around 20 
min.); 3. trans-cinnamic acid (around 36 min.), 4. aromadendrin (38 
min.) 5. isosakuretin (around 48 min.) and 6.Artepillin C (around 
61 min.). The chromatograms were plotted at 275 nm, using the 
RP-HPLC, C18 (Shim-pack, CLC-ODS (M), 25 cm x 4.6) column 
and gradient elution with methanol and acidic water (formic acid 
pH=2.7). 
 
Antimicrobial activity of EPP-AF® Extracts – 
Minimal Bactericidal Concentration (MBC) 
The three batches of EPP-AF® studied, showed in 
vitro antimicrobial activity against all the tested mi-
croorganisms (Table 2). The statistical analysis 
demonstrated no significant difference (p0.05) 
among the three batches (A, B and C). Gram positive 
bacteria (Staphylococci) were more sensitive to 
EPP-AF® than Gram negative bacteria (P. aeruginosa, 
K. pneumoniae and E. coli) (p<0.01).  
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Table 2: Minimum bactericidal concentration (MBC) of the 
three batches of standardized propolis extract (EPP-AF® - 
A, B and C) (n=3). 
Microorganism  MBC 
(mg/mL) 
 
Aa 
Mean 
(SD) 
Bb 
Mean (SD) 
Cc 
Mean 
(SD) 
Pseudomonas aeruginosa 
ATCC 27853 
14.05 
(0.00) 
13.93 (0.00) 14.00 
(0.00) 
Klebsiella pneumoniae ATCC 
10031 
14.05 
(0.00) 
13.93 (0.00) 14.00 
(0.00) 
Escherichia coli ATCC 25922 14.05 
(0.00) 
13.93 (0.00) 14.00 
(0.00) 
Staphylococcus aureus ATCC 
25923 
7.02 (0.00) 6.96 (0.00) 7.00 (0.00) 
Staphylococcus aureus ATCC 
43300 
3.51 (0.00) 3.48 (0.00) 3.50 (0.00) 
Staphylococcus epidermidis 
ATCC 14990 
7.02 (0.00) 6.96 (0.00) 7.00 (0.00) 
a Batch 10/08 of EPP-AF® (11.24% w/v dry propolis extract).  
b Batch 1440110 of EPP-AF® (11.15% w/v dry propolis extract). 
c Batch 1400410 of EPP-AF® (11.20% w/v dry propolis extract). 
 
 
Wound Healing activity 
The histological slices obtained from animals 
treated with saline (control), gel without propolis and 
gel containing 1.2%, 2.4% and 3.6% w/v (dry matter) 
of propolis during the three days treatment. Figure 2A 
corresponds to the injured tissue treated with saline, 
while Figures 2 B and C depict the treatment with gel 
in the absence of propolis. The histological section 
shows the onset of the healing process, where there is 
an intense presence of immune cells, especially the 
cream leukocytes (arrows). 
Treatment with the sample 1, which con-
tained1.2% propolis shows the healing process is 
more developed. In addition there is the presence of a 
large number of newly formed vessels, fibroblasts and 
the presence of plasma cells (Figure 3A and B). With 
this treatment it can be seen that epithelial cells are 
organizing clots just below the initial lesion (arrow - 
Figure 3A) and the presence of collagen fibers was 
noted (Figure 3 B).  
Treatment with the sample 2, containing 2.4% 
propolis demonstrated earlier healing than that ob-
served with sample 1. Figure 4A shows the closure of 
the injury, where there is a region with epithelial cells 
and the presence of organized collagen fibers (arrow). 
Subcutaneously (Fig. 4B) it is clear the tissue contains 
fibroblasts and collagen, and also a large number of 
mitotic cells (arrows), showing that propolis stimu-
lates cell proliferation and tissue repair. 
 
 
 
Figure 2: Photograph showing the healing process of the control group (A) and the group treated with gel in the absence of propolis (B 
and C) after 3 days of treatment. Slices of 6 m were obtained and stained with Masson´s trichromic. a) Lesions treated with saline 
(control). Start of the healing process (100x magnification); b) Lesions treated with gel without propolis. Start of the healing process (100x 
magnification); c) Lesions treated with gel without propolis. Cream leukocitary cells (arrow) observed just below the initial clot (*) (400X 
magnification). 
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Figure 3: Photograph showing the healing process after three 
days of treatment with the gel containing 1.2% of dry extract of 
propolis. a) Lesions treated with gel containing standardized 
extract of propolis (1.2%) in the subcutaneous tissue. The reor-
ganization of epithelial cells (c) and increased collagen fibers were 
observed just below the initial clot (*). Slices of 6 m were ob-
tained and stained with Masson´s trichromic (100x magnification); 
b) lesions treated with gel containing standardized extract of 
propolis (1.2%). There are a large number of fibroblasts synthe-
sizing collagen (arrow). Slices of 6 m were obtained and stained 
with Masson´s trichromic (400X magnification). 
 
Figure 4C corresponds to the treatment per-
formed with sample 3, which contained 3.6% propo-
lis, where it is possible to see the tissue is completely 
reconstituted, where all the corneal layer is formed, 
consisting of properly organized epithelial tissue (1). 
The subcutaneous region presents a dense and 
well-structured tissue with the presence of collagen, 
however without the required extracellular matrix.  
Histological findings have shown that with just 
one application of the gels containing EPP-AF®, an 
organized tissue was formed and maintained with 
physiological functions (Figure 4). It could also be 
observed that the healing effect was almost the same 
between the concentrations of 2.4% and 3.6%. The 
repetition of the applications was more effective when 
we compare the morphometric analysis of the healing 
area. The analysis noted that the area of newly formed 
tissue was significantly higher for the individual ap-
plications of samples 2 and 3 when compared to 
sample 1 application. No significant difference in 
morphometric area was observed between samples 2 
and 3 (p>0.05). 
 
 
Figure 4: Photograph showing the healing process after three 
days of treatment with the gels containing either 2.4% or 3.6% 
propolis. Slices of 6 m were obtained and stained with Masson´s 
trichromic. a) Lesions treated with the 2.4% propolis gel. Closing 
of the lesion in the epithelial layer (1) and subcutaneously (2) there 
is a large number of fibroblasts synthesizing collagen (arrow) (100x 
magnification); b) Lesion treated with the 2.4% propolis gel. 
Subcutaneously (2) there is an increase of collagen fibers and a 
large number of cells undergoing mitosis (arrow) (400X magnifi-
cation); c) Lesions treated with the 3.6% propolis gel. Wound area 
completely rebuilt, the epithelium (1) is already presented in 
several layers forming the corneal region. Subcutaneously (2) 
thicker collagen fibers (arrow) were observed (400X magnifica-
tion). 
 
Int. J. Biol. Sci. 2012, 8 
 
http://www.biolsci.org 
518 
Through the data presented with increasing 
concentration of propolis, a greater number of mitotic 
cells were observed, suggesting a role for this product 
as a stimulator of fibroblast growth. The present re-
sults showed the healing activity of the gel containing 
EPP-AF®, especially with samples 2 and 3, after three 
days of treatment, while in the control group, seven 
days was required to obtain tissue repaired. 
Antimicrobial activity of Thermoreversible 
Gels – Minimal Inhibitory Concentration (MIC) 
Samples 1 and 2 were not effective against the 
tested microorganisms (Table 3). However, sample 3 
showed in vitro antimicrobial activity against all mi-
croorganisms (Table 3). Sample 3 was statistically 
more efficacious in inhibiting growth of the microor-
ganisms than samples 1 and 2 (p0.001). No signifi-
cant difference was found between samples 1 and 2 
(p0.05). Control sample (without EPP-AF®) was not 
effective against the tested microorganisms. 
Discussion 
Sforcin and Bankova (2011) [24] presented the 
difficulties in developing a drug based on propolis, 
although numerous scientific data-sets have shown 
the biological activities of propolis and its safety. The 
origin of propolis, its mode of production and chem-
ical composition can be different, hindering obtaining 
a safe and effective medicine. 
Batch variability is a common drawback in the 
manufacture of plant extracts. Medicinal use of natu-
ral compounds must rely on appropriate quality, 
safety, and efficacy requisites. In this regard, 
batch-to-batch reproducibility is essential to ensure 
consistent quality. In the present study, compounds 
such as phenolics, cinnamic acid derivatives, flavo-
noids (aromadendrin and isosakuranetin), a repre-
sentative of prenylated p-coumaric acids, artepillin C, 
an important and internationally recognized bi-
omarker for propolis of the Brazilian type [15;18].  
The results presented in this study, demon-
strated for the first time in the literature the chemical 
reproducibility of three independent batches of prop-
olis extract compared with six standards. Almeida et 
al. (2010) studied the chemical and functional repro-
ducibility of the extracts from Castanea sativa, by 
comparing the fingerprint of the three extracts with 
respect of the phenolic composition. Although the 
chromatographic profile showed several peaks, like in 
this study, only the hyperoside, isoquercitrin, rutin 
and ellagic acid were identified [25]. The identifica-
tion and analysis of some applicable chemical markers 
(not all peaks found in the chromatogram) is common 
in phytotherapeutic studies because it is quite difficult 
to identify all compounds in the sample. Nonetheless, 
the batch-to-batch reproducibility can be demon-
strated considering a group of standards. Then, in the 
presented investigation, although all the peaks pre-
sented in the chromatograms were not identified 
(studies running), the chemical reproducibility ob-
tained is a remarkable fact considering the area of 
research in question. Working in the field of techno-
logical innovation, these findings suggest that propo-
lis EPP-AF® can be used as a drug. 
 
Table 3 Minimum inhibitory concentration (MIC) of the formulations (samples 1, 2 and 3) containing the batches A, B and 
C of standardized propolis extract (EPP-AF®) (n=3). 
Microorganism MIC (mg/mL) 
Sample 1a Sample 2b Sample 3c 
Ad 
Mean (SD) 
Be 
Mean (SD) 
Cf 
Mean (SD) 
A 
Mean (SD) 
B 
Mean (SD) 
C 
Mean (SD) 
A 
Mean (SD) 
B 
Mean (SD) 
C 
Mean (SD) 
P. aeruginosa ATCC 27853  6 
(0.00) 
 6 
(0.00) 
 6 
(0.00) 
 12 
(0.00) 
 12 
(0.00) 
 12 
(0.00) 
18 
(0.00) 
18 
(0.00) 
18 
(0.00) 
K. pneumoniae 
ATCC 10031 
 6 
(0.00) 
 6 
(0.00) 
 6 
(0.00) 
 12 
(0.00) 
 12 
(0.00) 
 12 
(0.00) 
18 
(0.00) 
18 
(0.00) 
18 
(0.00) 
E. coli 
ATCC 25922 
 6 
(0.00) 
 6 
(0.00) 
 6 
(0.00) 
 12 
(0.00) 
 12 
(0.00) 
 12 
(0.00) 
18 
(0.00) 
18 
(0.00) 
18 
(0.00) 
S. aureus  
ATCC 25923 
 6 
(0.00) 
 6 
(0.00) 
 6 
(0.00) 
 12 
(0.00) 
 12 
(0.00) 
 12 
(0.00) 
9 
(0.00) 
9 
(0.00) 
9 
(0.00) 
S. aureus  
 ATCC 43300 
 6 
(0.00) 
 6 
(0.00) 
 6 
(0.00) 
 12 
(0.00) 
 12 
(0.00) 
 12 
(0.00) 
9 
(0.00) 
9 
(0.00) 
9 
(0.00) 
S. epidermidis ATCC 14990  6 
(0.00) 
 6 
(0.00) 
 6 
(0.00) 
 12 
(0.00) 
 12 
(0.00) 
 12 
(0.00) 
9 
(0.00) 
9 
(0.00) 
9 
(0.00) 
a 1.2% (w/v) propolis dry extract; b 2.4% (w/v) propolis dry extract; c 3.6% (w/v) propolis dry extract; d Batch 010/08 of EPP-AF®; e Batch 
1440110 of EPP-AF®; f Batch 1400410 of EPP-AF®. 
 
Int. J. Biol. Sci. 2012, 8 
 
 
http://www.biolsci.org 
519 
The microorganisms studied P. aeruginosa, K. 
pneumoniae, E. coli, S. aureus and S. epidermidis. P. ae-
ruginosa are the most frequently isolated from injuries 
and burn wound, followed by K. pneumoniae, E. coli, S. 
aureus and the coagulase-negative staphylococci [1]. S. 
aureus ATCC 43300 is a methicillin-resistant S. aureus 
(MRSA). These strains are resistant to all penicillins, 
cephalosporins and carbapenems. However, EPP-AF® 
showed antimicrobial activity against these microor-
ganisms, demonstrating the functional reproducibility 
of EPP-AF® similar to that obtained by Almeida et al. 
(2010) in the case of antioxidant activity of Castanea 
sativa [25]. Furthermore, EPP-AF® killed S. aureus 
ATCC 43300 with a range of concentration 3.48 – 3.51 
mg/ml, while it killed other staphylococci with higher 
concentrations (6.96 - 7.02 mg/ml) (Table 2). 
Gram-negative bacteria were killed with higher con-
centrations of EPP-AF®. Erkmen and Özcan (2008) 
[26] reported that Gram-positive bacteria were more 
susceptible to Turkish propolis extracts than 
Gram-negative bacteria. Similar result occurred with 
the propolis evaluated in this work.  
Until the present moment, the mechanisms of 
action related to the biological activities of propolis 
remains unknown. Menna-Barreto et al. (2009) 
showed that susceptibility of T. cruzi treated with 
propolis was affected by the reservosomes, suggesting 
a failure in the lipid metabolism, affecting membrane 
fluidity and leading to cell lysis [27]. Takaisi & 
Schilcher (1994) suggested that the antimicrobial ac-
tivity of propolis is due to a combined action of pi-
nocembrine, galangin and caffeic acid phenethyl ester 
(CAPE), whose action is based on the inhibition of 
bacterial RNA polymerase [28]. However, the flavo-
noid compounds presented in this works are charac-
teristic of propolis originating from Poplar buttons 
(Populus sp.) and therefore referring of European 
propolis, hence such data cannot simply be extrapo-
lated to the Brazilian propolis [24]. Furthermore, the 
research of CAPE in the EPP-AF® demonstrated that 
this compound is not present in its composition (data 
not shown). 
Recently, studies done by our group using Sac-
charomyces cerevisiae models demonstrated that short 
exposure to the propolis standardized extract 
(EPP-AF®) was able to induce cell death by apoptosis, 
while contact for longer periods caused necrosis [14]. 
The results of De Castro et al. (2011) also indicate that 
cytochrome c and endonuclease G (Nuc 1p) are in-
volved in cell death induced by propolis and that the 
metacaspase YCA1 gene is one of the important me-
diators in this induction. Systems biology revealed 
enrichment for genes involved in the mitochondrial 
electron transport chain, vacuolar acidification, nega-
tive regulation of transcription from the RNA poly-
merase II promoter, regulation of macroautophagy 
associated with protein targeting to vacuoles, and 
cellular responses to starvation. Validation studies 
indicated that propolis sensitivity is dependent on the 
mitochondrial function and that vacuolar acidification 
and autophagy are important for cell death caused by 
propolis [14]. The same research group evaluated the 
six standards chosen to the standardization of the 
EPP-AF®, individually and combined, in Saccharomy-
ces cerevisiae models, however no positive results were 
obtained with the standards when applied individu-
ally (1, 2, 5, 10, 25, 50, 100 and 200 µg/ml) or com-
bined (100 µg/ml each one) similar to the observation 
made by Urushisaki et al. (2011) using an antiinflu-
enza model [29].  
After the chemical and biological characteriza-
tion of EPP-AF®, the next step was to develop an in-
terestingly pharmaceutical preparation, with a dif-
ferent and advantageous presentation to encourage 
patient compliance throughout the course of the 
treatment. For that, a polymeric system based on 
poloxamer 407 gel was proposed, due to the thermo 
reversible behavior and the stable arrangement of 
micelles that offered a stable and beautiful prepara-
tion. Also, the safety of this gel has previously been 
evaluated in in vitro and in vivo models [15]. 
Inflammation can be divided into acute, chronic 
and inflammation related to immunity. Any factor 
that induces the tissue damage could be described as 
the pathogenesis of inflammation. There are two 
types of factors that induce inflammation: inflamma-
tory stimulating factor including physical stimuli, 
such as burns and surgery, or chemicals such as acids, 
alkalis, allergens; and biochemical (microorganisms, 
parasites, endotoxins, toxins). Another route of stim-
ulating inflammation includes histamine, bradykinin, 
prostaglandins, platelet activating factor and 
pro-inflammatory stimulation factors (TNF-α, IL-1, 
IL-6, cellular chemotaxis factor, etc.), among others 
[30].  
The wound healing process occurs through a se-
ries of events coordinated and mediated by cytokines 
that require action in concert of many cell types. The 
first phase of the healing process is governed primar-
ily by various inflammatory cells that accumulate 
within the wound. Platelets are among the first in-
flammatory mediators to arrive at the injury site, 
while neutrophils and macrophages arrive during the 
first two days after the injury occurred and typically 
precede the influx of fibroblasts, lymphocytes and 
endothelial cells. The well-orchestrated series of 
events within which these cell types interact includes 
the release of cytokines, growth factor and other bio-
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active molecules, such as free radicals [31] that when 
successful culminate in the functional restoration of 
tissue integrity. 
In the present study, some samples of poloxamer 
gels were prepared with different concentrations of 
the propolis dry extract, since one of the objectives 
was to determine the best concentration of the propo-
lis extract to promote wound healing and to kill or 
suppress the growth of microorganisms presented in 
burnt patients wounds.  
The results demonstrated that the presence of 
propolis offered different results when compared to 
control (saline) and the poloxamer gel (without prop-
olis), suggesting that samples 2 and 3 demonstrated 
better results. It is important to mention that the ma-
trix formed is appropriate to the final objective, since 
larger quantities, than is required for the formation of 
reepithelization, can cause hypertrophic scars and 
keloids, due to the excessive deposition of extracellu-
lar matrix, mainly collagen, as well as other sub-
stances, such as glycoproteins, glycosaminoglycans 
and proteoglycans [32]. When antimicrobial activities 
of the gels were analyzed, samples 1 and 2 demon-
strated absence of antibacterial activity against the 
bacterial strains tested. These samples contained 
lower concentrations of dry propolis extract (1.2 and 
2.4%, respectively). Sample 3 (3.6% propolis), howev-
er, was effective against all microorganisms, suggest-
ing this thermoreversible gel is the best option to 
achieve the objective of this work. 
In the present model of study, epithelization 
concluded seven days after the injury. By this time, 
the structure of the subcutaneous tissue and collagen 
fibers, which provide support to the tissue, are com-
pletely reconstituted and a reorganization of the epi-
thelial layer is observed, a process that culminates 
with the closing of the injury. In the treatments 
showed, histological sections were performed three 
days after the injury, showing the relevance of the 
results obtained.  
The anti-inflammatory effect of propolis has 
been attributed to various mechanisms such as inhib-
iting the production of eicosanoids and nitric oxide, 
antioxidant action, modulation of calcium ion mobi-
lization, angiogenesis and anti-leukocyte activity [33]. 
In the results presented here, it was observed that, 
when treated with the propolis gel, histological sec-
tions showed a decrease of leukocytes, the presence of 
new blood vessels (angiogenesis) and fibroblasts, 
corroborating to the mechanisms previous related. 
The increased healing activity has been at-
tributed to increased collagen formation and angio-
genesis. Antioxidants have been shown to play a sig-
nificant role in the healing and anti-inflammatory 
process [34]. This information has also been demon-
strated in studies with asiaticoside, obtained from 
Centella asiatica, which also has an important healing 
action and demonstrated the increase of antioxidants 
in the new tissue formed after application of the ac-
tive. This data suggested that the increase in antioxi-
dant damaged areas can be an important factor in the 
healing process [31]. 
Numerous substances have been identified in 
propolis [35]. Its pharmacological properties, espe-
cially those related to antimicrobial, an-
ti-inflammatory and wound healing properties, were 
mainly attributed to the presence of flavonoids and 
phenolic compounds [8]. It is scientifically proven that 
flavonoids reduce lipid peroxidation not only by 
preventing or delaying the onset of cellular necrosis, 
but also by increasing vascularization. It is believed 
that any drug that inhibits lipid peroxidation in-
creases the feasibility of collagen fibers by increasing 
resistance and circulation, preventing cell damage 
and promotion of cell synthesis [36]. Furthermore, the 
flavonoids and terpenoids are also responsible for 
promoting the healing process of injuries, mainly due 
to their astringent and antimicrobial characteristics 
that appear to be responsible for the contraction of the 
lesion and the increased rate of epithelialization [36]. 
Also, flavonoids exhibit inhibitory activity of cy-
clooxygenase (COX) and lipooxigenase, reduction of 
prostaglandin E2 (PGE2) and expression of the in-
ducible isoform of COX (COX-2).  
Conclusion 
In conclusion, the results of the chemical and bi-
ological characterization demonstrated the 
batch-to-batch reproducibility of the EPP-AF®, con-
sidering the standards and microorganisms studied. 
Furthermore, this extract was effective against all mi-
croorganisms tested. The results suggest that a new 
thermoreversible pharmaceutical form containing 
propolis as active ingredient can offer an alternative 
therapeutics to treat skin injuries, since this prepara-
tion was effective against all microorganisms tested 
and demonstrated favorable result on the wound 
healing model used. 
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